Related Experiment Video
Updated: Jul 6, 2025

Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids
Published on: June 28, 2019
Omega-3 fatty acids for cardiovascular event lowering
Gurleen Kaur1, R Preston Mason1,2, Ph Gabriel Steg3
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
High-intensity statin therapy effectively lowers LDL-C but residual cardiovascular risk persists. Icosapent ethyl, a purified EPA formulation, shows promise in reducing cardiovascular events in high-risk patients with hypertriglyceridemia.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Low-density lipoprotein cholesterol (LDL-C) is a primary target for atherosclerotic cardiovascular disease (ASCVD) risk reduction.
- Residual cardiovascular risk remains a significant concern in high-risk populations despite effective LDL-C lowering therapies.
- Triglycerides are causally linked to ASCVD, but triglyceride-lowering therapies have yielded mixed results.
Purpose of the Study:
- To review evidence on omega-3 fatty acids for cardiovascular event reduction.
- To discuss the clinical implementation of omega-3 fatty acids based on trial data and guidelines.
- To highlight the role of icosapent ethyl in managing residual risk.
Main Methods:
- Systematic review of clinical trials investigating omega-3 fatty acids for cardiovascular outcomes.
- Analysis of guideline recommendations for triglyceride-lowering therapies.
- Evaluation of data supporting icosapent ethyl's efficacy.
Main Results:
- Icosapent ethyl, a purified eicosapentaenoic acid (EPA) formulation, demonstrated compelling evidence in reducing residual cardiovascular risk.
- Studies show mixed results for other omega-3 fatty acid therapies in cardiovascular outcomes.
- Effective LDL-C lowering does not eliminate residual risk in many high-risk patients.
Conclusions:
- Icosapent ethyl represents a significant advancement in managing residual cardiovascular risk in patients with hypertriglyceridemia on statin therapy.
- Further research and guideline updates are needed to optimize the use of omega-3 fatty acids.
- Addressing residual risk beyond LDL-C remains a critical area in cardiovascular disease prevention.
Related Concept Videos
Structure of Lipids
Lipids: Dietary Sources and Requirements
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Anticoagulant Drugs: Low-Molecular-Weight Heparins

